• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (5071025)   Today's Articles (71)
For: Laheij AMGA, van de Donk NWCJ. Characterization of dysgeusia and xerostomia in patients with multiple myeloma treated with the T-cell redirecting GPRC5D bispecific antibody talquetamab. Support Care Cancer 2023;32:20. [PMID: 38092979 DOI: 10.1007/s00520-023-08233-0] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/26/2023] [Accepted: 12/03/2023] [Indexed: 12/18/2023]
Number Cited by Other Article(s)
1
Pelland AA, Dumas M, Lemieux-Blanchard É, LeBlanc R, Côté J, Boudreault JS, Duquette D, Kaedbey R, Lalancette M, Larose F, Nikonova A, Pavic M, Shamy A, Roy J, Sebag M, Trudel S, Claveau JS. Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma. Curr Oncol 2025;32:238. [PMID: 40277794 PMCID: PMC12025952 DOI: 10.3390/curroncol32040238] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/29/2025] [Revised: 04/17/2025] [Accepted: 04/17/2025] [Indexed: 04/26/2025]  Open
2
Bal S. Monumen-TAL progress in the treatment of relapsed multiple myeloma. Lancet Haematol 2025;12:e235-e236. [PMID: 40090351 DOI: 10.1016/s2352-3026(25)00009-2] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/05/2025] [Accepted: 01/17/2025] [Indexed: 03/18/2025]
3
Zweegman S. Supportive care in myeloma-when treating the clone alone is not enough. HEMATOLOGY. AMERICAN SOCIETY OF HEMATOLOGY. EDUCATION PROGRAM 2024;2024:569-581. [PMID: 39643986 PMCID: PMC11665544 DOI: 10.1182/hematology.2024000579] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 12/09/2024]
4
Pan D, Richter J. Management of Toxicities Associated with BCMA, GPRC5D, and FcRH5-Targeting Bispecific Antibodies in Multiple Myeloma. Curr Hematol Malig Rep 2024;19:237-245. [PMID: 39145912 DOI: 10.1007/s11899-024-00740-z] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Accepted: 07/31/2024] [Indexed: 08/16/2024]
5
van de Donk NW, Rasche L, Sidana S, Zweegman S, Garfall AL. T Cell-Redirecting Bispecific Antibodies in Multiple Myeloma: Optimal Dosing Schedule and Duration of Treatment. Blood Cancer Discov 2024;5:388-399. [PMID: 39321136 PMCID: PMC11528190 DOI: 10.1158/2643-3230.bcd-24-0124] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/17/2024] [Revised: 07/22/2024] [Accepted: 09/11/2024] [Indexed: 09/27/2024]  Open
6
An JY, Pan MM, Ouyang HY, Mi JQ. [Research progress in targeting GPRC5D for the treatment of multiple myeloma]. ZHONGHUA XUE YE XUE ZA ZHI = ZHONGHUA XUEYEXUE ZAZHI 2024;45:883-888. [PMID: 39414618 PMCID: PMC11518913 DOI: 10.3760/cma.j.cn121090-20240322-00109] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Received: 03/22/2024] [Indexed: 10/18/2024]
7
Mansilla-Polo M, Martín-Torregrosa D, Martínez-Cozar V, Arnao-Herraiz M, Botella-Estrada R. Dermatological toxicities of talquetamab, a new bispecific antibody: case series and literature review. J Dtsch Dermatol Ges 2024;22:1282-1286. [PMID: 39094121 DOI: 10.1111/ddg.15502] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/29/2024] [Accepted: 05/29/2024] [Indexed: 08/04/2024]
8
Heerma van Voss MR, Molenaar RJ, Korst CLBM, Bartelink IH, Baglio SR, Kruyswijk S, de Ruijter M, Zweegman S, Kuipers MT, van de Donk NWCJ. T-cell redirecting bispecific antibody treatment in multiple myeloma: current knowledge and future strategies for sustained T-cell engagement. Expert Opin Biol Ther 2024;24:889-901. [PMID: 39185748 DOI: 10.1080/14712598.2024.2397436] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/25/2024] [Revised: 07/29/2024] [Accepted: 08/23/2024] [Indexed: 08/27/2024]
9
Braun A, Gouni S, Pulles A, Strati P, Minnema MC, Budde LE. Bispecific Antibody Use in Patients With Lymphoma and Multiple Myeloma. Am Soc Clin Oncol Educ Book 2024;44:e433516. [PMID: 38935881 DOI: 10.1200/edbk_433516] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 06/29/2024]
10
Chen LY, Kothari J. Supportive care measures for bispecific T-cell engager therapies in haematological malignancies. Curr Opin Support Palliat Care 2024;18:92-99. [PMID: 38652455 DOI: 10.1097/spc.0000000000000699] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/25/2024]
PrevPage 1 of 1 1Next
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA